AUTHOR CONTACT:
Douglass Turnbull
University of Newcastle upon Tyne, Newcastle upon Tyne, United Kingdom.
Phone: 44-191-222-8334
Fax: 44-191-222-8553
E-mail: d.m.turnbull@ncl.ac.uk
View the PDF of this article at: https://www.the-jci.org/press/19435.pdf
ACCOMPANYING COMMENTARY:
Tales from the crypt
AUTHOR CONTACT:
Eric A. Schon
Columbia University, New York, New York, USA.
Phone: 212-305-1665
Fax: 212-305-3986
E-mail: eas3@columbia.edu
View the PDF of this commentary at: https://www.the-jci.org/press/20249.pdf
**********************************************
The anti-oxidant thioredoxin helps prevent cardiac hypertrophy
In the November 3 issue of the Journal of Clinical Investigation Junichi Sadoshima and colleagues from the University of Medicine and Dentistry of New Jersey report that thioredoxin acts as an anti-oxidant in the heart and plays an essential role in regulating oxidative stress and preventing cardiac hypertrophy.
Although it has been suggested that thioredoxin acts as an anti-oxidant in cells, the extent of thioredoxin contribution to overall cellular anti-oxidant mechanisms has not been clearly demonstrated in any organs in vivo. Sadoshima and colleagues now demonstrate that the heart-specific overexpression of a dominant-negative form of thioredoxin in mice causes increased oxidative stress and stimulates cardiac hypertrophy via redox-sensitive mechanisms when the animal is at rest and also when subjected to pressure overload.
Therefore, both thioredoxin and its downstream target proteins may be an important therapeutic f
'"/>
Contact: Brooke Grindlinger
science_editor@the-jci.org
212-342-9006
Journal of Clinical Investigation
3-Nov-2003